arXiv subjects

Heiko Enderling

Publications and source records attributed to Heiko Enderling.

4 recordsLinked to original sources

arXiv2026

Uncertainty Quantification-Incorporated Ensemble Model for Personalized Prediction of Severe Radiotherapy-Induced Immunosuppression Among Esophageal Cancer Patients

Severe radiation-induced lymphopenia (RIL), specifically Grade 4 RIL (G4RIL), is a frequent immune toxicity and a strong predictor of poor survival for esophageal cancer patients undergoing concurrent chemoradiation therapy. This study developed an uncertainty-incorporated ensemble machine learning model to predict Absolute Lymphocyte Count (ALC) nadir using baseline clinical and dosimetric variables, supporting treatment decisions such as proton therapy selection and dose distribution optimization. A cohort of 1,491 esophageal cancer patients treated with photon or proton therapy between July 2001 and April 2022 was analyzed. A weighted ensemble model was constructed using clinical features and dosimetric variables, including the composite dosimetric score (CDS) derived from radiation dose distributions. To quantify individual-level predictive uncertainty, Cross-Residual Conformal Prediction (CRCP) was developed and evaluated against standard conformal prediction methods. Proton therapy patients maintained a significantly higher mean ALC nadir than photon patients (0.33 vs. 0.25 K/uL). The ensemble model achieved a mean absolute error of 0.0926 K/uL for ALC nadir prediction and an ROC-AUC of 0.78 for G4RIL classification. Baseline ALC, Planning Target Volume, and CDS were the most influential predictors. CRCP achieved competitive prediction interval widths with mathematically guaranteed coverage, offering a favorable balance between interval width and coverage accuracy. This framework enables risk-aware, personalized clinical decision-making in radiation oncology.

q-bio.QM↗

arXiv2026

2D reaction-diffusion model-based biopsy simulation for dynamic tumor growth parameter estimation

Once diagnosed, cancer requires a fast, reliable and preferably cost-efficient assessment of the current state and potential progression of the disease. A new method for estimating tumor cell diffusivity $D$ and proliferation rate $γ$ in the context of the mechanistic reaction-diffusion equation from single-point-in-time routine biopsies aims to deliver just that, and quantities computed from the parameter estimates have recently been tested as a new biomarkers for risk-stratification in radiotherapy. Here, we extend the findings of this previous work by providing a first theoretical validation. The method is applied to in-silico biopsies which are generated by solving the two-dimensional reaction-diffusion equation for different growth terms (exponential and logistic) with a Dirac-Delta initial condition, and transforming the continuous results into spatial point patterns via a form of reverse coarse-graining. If no information about tumor age is used, in short-term experiments the original dispersion length $\sqrt{D/γ}$ could be retrieved with a relative root mean squared error (RRMSE) of around 8% and an $\text{R}^2$-value of 0.97. In long-term experiments, the RRMSEs ranged from 8 to 14% and the $\text{R}^2$-values from 0.75 to 0.98. The scaled front velocity $\sqrt{D \cdotγ}$, which can only be estimated if information about tumor age is available, was retrieved with an RRMSE of 7% and an $\text{R}^2$ of 0.98 in both, the short-term and the long-term experiments.

q-bio.OT↗

arXiv2023

Predicting radiotherapy patient outcomes with real-time clinical data using mathematical modelling

Longitudinal tumour volume data from head-and-neck cancer patients show that tumours of comparable pre-treatment size and stage may respond very differently to the same radiotherapy fractionation protocol. Mathematical models are often proposed to predict treatment outcome in this context, and have the potential to guide clinical decision-making and inform personalised fractionation protocols. Hindering effective use of models in this context is the sparsity of clinical measurements juxtaposed with the model complexity required to produce the full range of possible patient responses. In this work, we present a compartment model of tumour volume and tumour composition, which, despite relative simplicity, is capable of producing a wide range of patient responses. We then develop novel statistical methodology and leverage a cohort of existing clinical data to produce a predictive model of both tumour volume progression and the associated level of uncertainty that evolves throughout a patient's course of treatment. To capture inter-patient variability, all model parameters are patient specific, with a bootstrap particle filter-like Bayesian approach developed to model a set of training data as prior knowledge. We validate our approach against a subset of unseen data, and demonstrate both the predictive ability of our trained model and its limitations.

q-bio.TO↗

arXiv2013

A High-Performance Cellular Automaton Model of Tumor Growth with Dynamically Growing Domains

Tumor growth from a single transformed cancer cell up to a clinically apparent mass spans many spatial and temporal orders of magnitude. Implementation of cellular automata simulations of such tumor growth can be straightforward but computing performance often counterbalances simplicity. Computationally convenient simulation times can be achieved by choosing appropriate data structures, memory and cell handling as well as domain setup. We propose a cellular automaton model of tumor growth with a domain that expands dynamically as the tumor population increases. We discuss memory access, data structures and implementation techniques that yield high-performance multi-scale Monte Carlo simulations of tumor growth. We present simulation results of the tumor growth model and discuss tumor properties that favor the proposed high-performance design.

q-bio.QM↗